T2 Biosystems, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share data) (Unaudited) Three Months Ended December 31, Twelve Months Ended

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

	Three Months Ended December 31,		Twelve Months Ended December 31,
	2016		2015		2016		2015
Revenue:
Product revenue	$	579		$	343		$	1,747		$	599
Research revenue	331		668		2,333		2,214
Total revenue	910		1,011		4,080		2,813
Costs and expenses:
Cost of product revenue	2,171		910		6,872		1,740
Research and development expenses	5,851		6,638		24,009		25,362
Selling, general and administrative expenses	5,795		5,008		24,077		19,094
Total costs and expenses	13,817		12,556		54,958		46,196
Loss from operations	(12,907	)	(11,545	)	(50,878	)	(43,383	)
Interest expense, net	(1,682	)	(513	)	(4,098	)	(1,967	)
Other income, net	40		26		172		60
Net loss and comprehensive loss	$	(14,549	)	$	(12,032	)	$	(54,804	)	$	(45,290	)
Net loss per share - basic and diluted	$	(0.48	)	$	(0.56	)	$	(2.11	)	$	(2.21	)
Weighted-average number of common shares used in computing net loss per share	30,457,063		21,322,799		26,015,751		20,501,748

Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)

	December 31, 2016		December 31, 2015
Assets
Current Assets:
Cash and cash equivalents	$	73,488		$	73,662
Accounts receivable	327		369
Prepaid expenses and other current assets	820		838
Inventory, net	803		683
Total current assets	75,438		75,552
Property and equipment, net	13,589		10,655
Restricted cash	260		260
Other assets	281		358
Total assets	$	89,568		$	86,825
Liabilities and stockholders equity
Current liabilities:
Accounts payable	$	962		$	1,228
Accrued expenses and other current liabilities	4,908		4,162
Current portion of notes payable	1,269		4,449
Current portion of lease incentives	301		268
Deferred revenue	2,445		2,146
Total current liabilities	9,885		12,253
Notes payable, net of current portion	39,504		26,121
Lease incentives, net of current portion	792		1,076
Other liabilities	49		436
Commitments and contingencies
Stockholders equity:
Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2016 and December 31, 2015; 30,482,712 and 24,175,381 shares issued and outstanding at December 31, 2016 and December 31, 2015, respectively	30		24
Additional paid-in capital	242,997		195,800
Accumulated deficit	(203,689	)	(148,885	)
Total stockholders equity	39,338		46,939
Total liabilities and stockholders equity	$	89,568		$	86,825

Full Press Release Details